NEW ORAL DRUGS...
Novartis shows promising data on oral MS treatment FTY720, which is easier to administer and shows better tolerability and efficacy in tests than existing products.:
" Novartis Turns The Heat On Serono's Rebif ....Not good news for Serono (SRA) who's key product is Rebif, an injectable MS treatment, says Lombard Odier Darier Hentsch. Serono isn't completely defenseless, as it's also developing an oral MS treatment. But although this product is roughly one year ahead of FTY720, Serono has yet to disclose data that is equally compelling......"